Get the Stockscreener App
12.08
1.28%
0.23
Entrada Therapeutics Inc stock is traded at $12.08, with a volume of 32,353.
It is up +1.28% in the last 24 hours and up +10.92% over the past month.
Entrada Therapeutics Inc is a clinical-stage biopharmaceutical company. It aims to transform the lives of patients by establishing a new class of medicines that engage intracellular targets that have long been considered inaccessible. The Company's Endosomal Escape Vehicle (EEV)-therapeutics are designed to enable the efficient intracellular delivery into a variety of organs and tissues, resulting in an improved therapeutic index and protein-based programs for the potential treatment of neuromuscular and ocular diseases, among others. Its oligonucleotide programs are in development for the potential treatment of people living with Duchenne, which are exon 44, 45, 50, and 51 skipping amenable. It has partnered to develop a clinical-stage program, VX-670, for myotonic dystrophy type 1.
See More
Previous Close:
$11.85
Open:
$11.97
24h Volume:
32,353
Relative Volume:
0.16
Market Cap:
$458.63M
Revenue:
$239.40M
Net Income/Loss:
$104.44M
P/E Ratio:
4.0811
EPS:
2.96
Net Cash Flow:
$-18.50M
1W Performance:
+0.18%
1M Performance:
+10.92%
6M Performance:
+129.92%
1Y Performance:
+9.21%
1-Day Range:
$11.75
$12.35
1-Week Range:
$11.21
$12.93
52-Week Range:
$4.93
$12.93
Entrada Therapeutics Inc Stock (TRDA) Company Profile
Name
Entrada Therapeutics Inc
Sector
Industry
Phone
857-305-1825
Address
ONE DESIGN CENTER PLACE, BOSTON
Compare TRDA vs VRTX, REGN, ARGX, ALNY, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
TRDA
Entrada Therapeutics Inc
|
12.00 | 452.90M | 239.40M | 104.44M | -18.50M | 2.96 |
|
VRTX
Vertex Pharmaceuticals Inc
|
477.35 | 120.48B | 12.07B | 3.95B | 3.19B | 15.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
779.93 | 81.05B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
747.00 | 46.33B | 4.16B | 1.29B | 734.26M | 19.59 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
325.31 | 42.26B | 3.71B | 313.75M | 465.38M | 2.2571 |
|
ONC
Beone Medicines Ltd Adr
|
297.45 | 32.87B | 5.36B | 287.73M | 924.18M | 2.5229 |
Entrada Therapeutics Inc Stock (TRDA) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Feb-11-26 | Initiated | Guggenheim | Buy |
| Jan-28-26 | Initiated | Oppenheimer | Outperform |
| Dec-06-24 | Initiated | ROTH MKM | Buy |
| Jan-05-24 | Initiated | Oppenheimer | Outperform |
| Apr-03-23 | Initiated | H.C. Wainwright | Buy |
Entrada Therapeutics Inc Stock (TRDA) Latest News
Entrada Therapeutics (TRDA) CEO gets RSUs, options and tax-related share sales - Stock Titan
Entrada Therapeutics (TRDA) CFO receives new equity grants and automatic tax share sales - Stock Titan
Entrada Therapeutics (TRDA) COO logs new RSU, option grants and tax share disposals - Stock Titan
Entrada Therapeutics (TRDA) grants RSUs and options as automatic share sales cover taxes - Stock Titan
Advancing Exon-Skipping and Undervalued DM1 Collaboration Underscore Buy Rating on Entrada Therapeutics - TipRanks
Entrada Therapeutics Announces Inducement Grants - National Today
Entrada Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Bitget
Entrada Therapeutics (NASDAQ:TRDA) Stock Rating Upgraded by Wall Street Zen - Defense World
The Technical Signals Behind (TRDA) That Institutions Follow - Stock Traders Daily
Entrada Therapeutics earnings beat by $0.04, revenue fell short of estimates - Investing.com Canada
Entrada Therapeutics (NASDAQ:TRDA) Posts Earnings Results, Beats Estimates By $0.38 EPS - MarketBeat
Entrada Therapeutics, Inc. (TRDA) Stock Analysis: Exploring A 54% Potential Upside - DirectorsTalk Interviews
Entrada Therapeutics Q4 net loss and EPS beat expectations - TradingView
Earnings Summary: Entrada Therapeutics Q4 - Benzinga
Entrada Therapeutics, Inc. SEC 10-K Report - TradingView
Entrada Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results - Bitget
Entrada Therapeutics (NASDAQ: TRDA) maps DMD, DM1 and ocular drug pipeline - Stock Titan
Entrada Therapeutics (TRDA) swings to 2025 loss while advancing DMD pipeline - Stock Titan
DMD trials advance as Entrada extends cash runway to Q3 2027 - Stock Titan
Analysts Offer Insights on Healthcare Companies: Day One Biopharmaceuticals (DAWN) and Xenon (XENE) - The Globe and Mail
Duchenne Muscular Dystrophy Clinical Trial Pipeline Gains Momentum: 75+ Companies Lead the Charge in Pioneering New Treatments | DelveInsight - StreetInsider
Entrada Therapeutics (TRDA) Soars 5.6%: Is Further Upside Left in the Stock? - MSN
Signal Recap: How does Entrada Therapeutics Inc compare to its peersQuarterly Risk Review & Community Trade Idea Sharing Platform - baoquankhu1.vn
What analysts say about Entrada Therapeutics Inc. stockM&A Rumor & Long-Term Safe Investment Plans - mfd.ru
Entrada Therapeutics’ (TRDA) “Buy” Rating Reaffirmed at HC Wainwright - Defense World
Entrada Therapeutics, Inc. (TRDA) Stock Analysis: Potential Upside of 67.57% Could Attract Investors - DirectorsTalk Interviews
Earnings Preview: Entrada Therapeutics, Inc. (TRDA) Q4 Earnings Expected to Decline - Finviz
Entrada Therapeutics (TRDA) to Release Earnings on Thursday - Defense World
EyePoint (EYPT) Surges 15.2%: Is This an Indication of Further Gains? - Yahoo Finance
HC Wainwright & Co. Reiterates Buy Rating on TRDA with $20 PT | - GuruFocus
Market Pulse: Should I trade or invest in Century Therapeutics IncJuly 2025 Big Picture & AI Optimized Trading Strategy Guides - baoquankhu1.vn
Independent Data Monitoring Committee Recommends Initiation of Cohort 2 at the Increased Dose of 12 mg/kg in Entrada Therapeutics' ELEVATE-44-201 Study - Bitget
Independent Data Monitoring Committee Recommends Initiation of Cohort 2 at the Increased Dose of 12 mg/kg in Entrada Therapeutics’ ELEVATE-44-201 Study - The Manila Times
Duchenne drug trial doubles dose to 12 mg/kg, aims at accelerated FDA approval - Stock Titan
Entrada Therapeutics Teases Data-Rich 2026 With DMD and DM1 Catalysts at Guggenheim Summit - Defense World
Precision Trading with Entrada Therapeutics Inc. (TRDA) Risk Zones - Stock Traders Daily
What are Entrada Therapeutics Inc.’s recent SEC filings showingLayoff News & AI Driven Stock Price Forecasts - mfd.ru
Why analysts remain bullish on Entrada Therapeutics Inc. stockBear Alert & Reliable Price Breakout Alerts - mfd.ru
Will Entrada Therapeutics Inc. stock gain from lower inflationJuly 2025 Patterns & Long-Term Capital Growth Ideas - mfd.ru
Entrada Therapeutics (NASDAQ:TRDA) Raised to Strong-Buy at Guggenheim - MarketBeat
Published on: 2026-02-13 04:19:34 - mfd.ru
Will Entrada Therapeutics Inc. benefit from rising consumer demandMarket Risk Analysis & High Conviction Buy Zone Alerts - mfd.ru
Can Entrada Therapeutics Inc. outperform under higher oil pricesEarnings Growth Summary & Low Risk Entry Point Tips - mfd.ru
This Olema Pharmaceuticals analyst begins coverage on a bullish note; here are top 4 initiations for Wednesday - MSN
Entrada Therapeutics, Inc. (TRDA) Stock Analysis: Exploring A Bold 67% Upside Potential - DirectorsTalk Interviews
TRDA: Q2 data expected to show strong safety and efficacy, de-risking future exon programs - TradingView
TRDA: Multiple clinical milestones in 2024 aim to validate a scalable, differentiated DMD platform - TradingView
Entrada Therapeutics (TRDA): Guggenheim Initiates Coverage With 'Buy' Rating | TRDA Stock News - GuruFocus
This Olema Pharmaceuticals Analyst Begins Coverage On A Bullish Note; Here Are Top 4 Initiations For Wednesday - Benzinga
Entrada Therapeutics, Inc. (NASDAQ:TRDA) Given Consensus Recommendation of "Hold" by Brokerages - MarketBeat
Update Recap: How does Entrada Therapeutics Inc compare to its peersGap Down & High Conviction Trade Alerts - baoquankhu1.vn
Entrada Therapeutics Inc Stock (TRDA) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.14%
0.19%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):